7-(m-fluorophenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile | 72851-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-(m-fluorophenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile
• 英文别名: 7-(3-fluoro-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile；7-(m-Fluorophenyl) pyrazolo[1,5-a]pyrimidine-3-carbonitrile；7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
• CAS: 72851-94-6
• 化学式: C₁₃H₇FN₄
• 分子量: 238.224
• InChiKey: FPWOERTWNJOEHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(m-fluorophenyl)-pyrazolo[1,5-a]pyrimidine-3-carbonitrile 以 硫酸 为溶剂， 生成 7-(3-fluorophenyl)-pyrazolo(1,5-a)pyrimidine-3-carboxamide
  参考文献：
  名称：

  5-(Substituted-amino)-8-(phenyl or

  摘要：

  这项披露描述了一种新颖的5-(取代氨基)-8-(取代苯基)-3H,6H,-1,-4,5a,8a-四氮杂蒽烯-3-酮，用于治疗哺乳动物的认知和相关神经行为障碍。

  公开号：

  US04916137A1

文献信息

• [EN] TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES<br/>[FR] PROCEDE EN DEUX PHASES DESTINE A LA SYNTHESE DE PYRAZOLOPYRIMIDINES SELECTIONNES
  申请人：MALLINCKRODT INC

  公开号：WO2005070931A1

  公开（公告）日：2005-08-04

  An improved method of making a substituted pyrazolopyrimidine. The method comprises reacting a aminopyrazole compound or a salt thereof with a substituted 1-oxo-2-propenyl-arene(-heterocycle) or a salt thereof under acidic conditions in a reaction medium including a two-phase mixture of an aqueous solution and a water-immiscible organic liquid. Specific substituted pyrazolopyrimidines include N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide and N-methyl-N-(3-3-[2-thienylcarbonyl]-pyrazolo[1, 5-a]-pyrimidin-7-yl}phenyl)acetamide.

  一种改进的制备取代吡唑吡咯嘧啶的方法。该方法包括在酸性条件下，将氨基吡唑化合物或其盐与取代的1-氧代-2-丙烯基芳烃（-杂环）或其盐在包括水溶液和水不相溶有机液体的两相混合物中反应。特定的取代吡唑吡咯嘧啶包括N-[3-(3-氰基吡唑[1,5-a]嘧啶-7-基)苯基]-N-乙醋胺和N-甲基-N-(3-3-[2-噻吩甲酰]-吡唑[1,5-a]-嘧啶-7-基}苯基)乙醋胺。
• Two-phase method for the synthesis of selected pyrazolopyrimidines
  申请人：Cantrell Lee Gary

  公开号：US20070155995A1

  公开（公告）日：2007-07-05

  An improved method of making a substituted pyrazolopyrimidine. The method comprises reacting a aminopyrazole compound or a salt thereof with a substituted 1-oxo-2-propenyl-arene(-heterocycle) or a salt thereof under acidic conditions in a reaction medium including a two-phase mixture of an aqueous solution and a water-immiscible organic liquid. Specific substituted pyrazolopyrimidines include N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide and N-methyl-N-(3-3-[2-thienyl-carbonyl]-pyrazolo[1,5-a]-pyrimidin-7-yl}phenyl)acetamide.

  一种改进的制备取代吡唑嘧啶的方法。该方法包括在酸性条件下，将氨基吡唑化合物或其盐与取代的1-氧代-2-丙烯基芳烃（杂环）或其盐在反应介质中反应，该反应介质包括水溶液和不溶于水的有机液体的两相混合物。具体的取代吡唑嘧啶包括N-[3-(3-氰基吡唑并[1,5-a]嘧啶-7-基)苯基]-N-乙酰胺和N-甲基-N-(3-3-[2-噻吩基-羰基]-吡唑并[1,5-a]-嘧啶-7-基}苯基)乙酰胺。
• Highly enantioselective Rh-catalyzed asymmetric reductive dearomatization of multi-nitrogen polycyclic pyrazolo[1,5-<i>a</i>]pyrimidines
  作者：Chaochao Xie、Guiying Xiao、Qianling Guo、Xiaoxue Wu、Guofu Zi、Wanjian Ding、Guohua Hou

  DOI：10.1039/d3sc02086j

  日期：——

  A highly enantioselective rhodium-catalyzed reductive dearomatization of 7-substituted pyrazolo[1,5-a]pyrimidines has been realized for the first time by two strategies to afford chiral 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines with excellent enantioselectivities of up to 98% ee. This method also provides an efficient approach for the synthesis of the powerful BTK inhibitor, zanubrutinib.

  首次通过两种策略实现了7-取代吡唑并[1,5- a ]嘧啶的高度对映选择性铑催化还原脱芳构化，得到手性4,5,6,7-四氢吡唑并[1,5- a ]嘧啶类化合物具有优异的对映选择性，高达 98% ee。该方法还为强效BTK抑制剂za​​nubrutinib的合成提供了一种有效的方法。
• 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0264773A1

  公开（公告）日：1988-04-27

  A compound of the formula: Ia or Ib wherein -may represent the presence of a double bond between the C6 and C7 position, la, or the absence of a double bond between the C6 and C7 position, Ib; R1 is hydrogen, bromo, chloro, carbamoyl, carboxamido, ethylcarboxylate, carboxyl, carboxyalkoxyl where alkoxy is (C1-C3), cyano, -CO-CF3, COONa, -CO-C(CH3)3. or where X is hydrogen, cyano, halogen or nitro; R2, R4 and R5 are hydrogen or lower alkyl(C1-C3); R3 ia hydrogen, alkyl(C1-C3), where R7 and R8 may be the same or different and are hydrogen, halogen, alkyl(C1-C3), nitro, alkoxy(Ci-C3), trifluoromethyl, N-alkyl(C1-C3)-N-alkanoxyl(C1-C3)-amino, acetylamino or N-alkylacetylamino where alkyl is (C1-C3), and R3 may be a monovalent radical of 3-thienyl, 2-pyridinyl, 3-pyridinyl or 4-pyridinyl, either of said pyridinyl radicals being optionally substituted with an alkyl radical R9, where alkyl is (C1-C4), and the structures of the monovalent 2-pyridinyl, 3-pyridinyl and 4-pyridinyl moieties are depicted respectively as: R6 is hydrogen, alkyl (C1-C3) or , where n is an integer from 1 to 4 inclusive; and Z is CH-, N-and -O-such that when Z is -CH, R10 is hydrogen, ethoxycarbonyl, phenyl, phenylmethyl, phenylmethyl(C1-C6)alkylenyl, when z is -0-, R10 is nil and when Z is N-, R10 is hydrogen, alkyl-(C1-C3), alkenyl(C2-C3), alkynyl(CrC3), cycloalkyl(C3-C6), dimethylaminoalkyl(CI-C3), hydroxyalkyl(C1-C3), ethylcarboxylate, alkyl(CI-C3)carbonyl, phenyl, benzyl, mono-or disubstituted benzyl [wherein the substituents are halogen, alkoxy(CI-C3), alkyl (C1-C3), and trifluoromethyl], benzoyl, 4-chlorophenylmethyl, 1,3-benzodioxol-5-yl-methyl, 1,3-benzodioxol-5-yl, 2-furanyl- carboxyl, 2-pyrimidinyl, 2-pyridinyl, 4-morpholinyl-2-oxoethyl, N-(1-methylethyl)-2-oxoethyl, 1-pyrrolidinyl-2-oxoethyl, bis(4-fluorophenyl)-methyl, 2-cyclohexylethyl, phenylcarboxamido, mono-and di-substituted phenylcarboxamido [wherein the substituents are trifluoromethyl, halogen and alkyl (CI-C3)], adamantanoyl, 3-phenoxypropyl, mono-and disubstituted phenyl [wherein the substituents are halogen, trifluoromethyl, alkoxy(CI-C3) and alkyl(C1-C3)], 5-chloro-2-methoxy phenylacetamide and (2-oxo-1-pyrrolidinyl)-2-butynyl and the pharmacologically acceptable acid addition salts thereof.

  式的化合物： Ia 或 Ib 其中 -may 代表在 C6 和 C7 位之间存在双键，即 la，或在 C6 和 C7 位之间不存在双键，即 Ib；R1 是氢、溴、氯、氨基甲酰基、羧基、羧酸乙酯、羧基、羧基烷氧基（其中烷氧基是 (C1-C3)）、氰基、-CO-CF3、COONa、 -或 其中 X 为氢、氰基、卤素或硝基；R2、R4 和 R5 为氢或低级烷基（C1-C3）；R3 为氢、烷基（C1-C3）、 其中 R7 和 R8 可以相同或不同，并且是氢、卤素、烷基（C1-C3）、硝基、烷氧基（Ci-C3）、三氟甲基、N-烷基（C1-C3）-N-烷氧基（C1-C3）-氨基、乙酰氨基或 N-烷基乙酰氨基，其中烷基是（C1-C3），R3 可以是 3-噻吩基的单价基、2-吡啶基、3-吡啶基或 4-吡啶基的单价基，其中任一吡啶基可选择被烷基 R9 取代，其中烷基为 (C1-C4)，2-吡啶基、3-吡啶基和 4-吡啶基的单价基的结构分别描述如下： R6 是氢、烷基（C1-C3）或 其中 n 是 1 至 4（含 4）的整数；当 Z 为-CH 时，R10 为氢、乙氧基羰基、苯基、苯基甲基、苯基甲基(C1-C6)烷烯基；当 Z 为-0-时，R10 为零；当 Z 为 N-时，R10 为氢、烷基(C1-C3)、烯基(C2-C3)、炔基(CrC3)、环烷基(C3-C6)、二甲基氨基烷基(CI-C3)、2-嘧啶基、2-吡啶基、4-吗啉基-2-氧代乙基、N-(1-甲基乙基)-2-氧代乙基、1-吡咯烷基-2-氧代乙基、双(4-氟苯基)甲基、2-环己基乙基、苯基甲酰胺基、单和双取代苯基甲酰胺基[其中取代基为三氟甲基、卤素和烷基 (CI-C3)]、金刚烷酰基、3-苯氧基丙基、单和二取代苯基[其中取代基为卤素、三氟甲基、烷氧基（CI-C3）和烷基（C1-C3）]、5-氯-2-甲氧基苯基乙酰胺和（2-氧代-1-吡咯烷基）-2-丁炔基及其药理学上可接受的酸加成盐。
• TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES
  申请人：MALLINCKRODT, INC.

  公开号：EP1713808A1

  公开（公告）日：2006-10-25